Syndax Pharmaceuticals Stock Five Year Return

SNDX Stock

USD 13.63 0.30 2.15%

Syndax Pharmaceuticals fundamentals help investors to digest information that contributes to Syndax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syndax Stock. The fundamental analysis module provides a way to measure Syndax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syndax Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Syndax Pharmaceuticals Company Five Year Return Analysis

Syndax Pharmaceuticals' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.

Five Year Return

(Mean of Monthly Returns - 1)

X

100%

More About Five Year Return | All Equity Analysis

Syndax Five Year Return Driver Correlations

Understanding the fundamental principles of building solid financial models for Syndax Pharmaceuticals is extremely important. It helps to project a fair market value of Syndax Stock properly, considering its historical fundamentals such as Five Year Return. Since Syndax Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Syndax Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Syndax Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	0.9	-0.93	-0.93	0.88	0.94	0.63	1.0	-0.64	0.98	0.96	0.59	0.6	0.73	0.61	0.78	0.88	0.9	0.72	0.9	0.94	0.89
Total Stockholder Equity	1.0		0.9	-0.93	-0.92	0.87	0.95	0.6	1.0	-0.65	0.98	0.95	0.58	0.62	0.72	0.6	0.78	0.88	0.91	0.71	0.9	0.94	0.89
Current Deferred Revenue	0.9	0.9		-0.82	-0.81	0.82	0.86	0.44	0.89	-0.47	0.88	0.82	0.4	0.68	0.52	0.37	0.84	0.72	0.81	0.85	0.81	0.85	0.92
Net Debt	-0.93	-0.93	-0.82		0.88	-0.92	-0.77	-0.65	-0.93	0.61	-0.91	-0.88	-0.53	-0.3	-0.69	-0.57	-0.72	-0.8	-0.81	-0.79	-0.8	-0.85	-0.91
Retained Earnings	-0.93	-0.92	-0.81	0.88		-0.91	-0.88	-0.66	-0.93	0.72	-0.95	-0.94	-0.71	-0.55	-0.88	-0.77	-0.88	-0.84	-0.76	-0.65	-0.76	-0.88	-0.81
Accounts Payable	0.88	0.87	0.82	-0.92	-0.91		0.74	0.62	0.87	-0.64	0.9	0.86	0.57	0.35	0.75	0.6	0.89	0.73	0.69	0.78	0.68	0.81	0.85
Short Term Investments	0.94	0.95	0.86	-0.77	-0.88	0.74		0.53	0.95	-0.64	0.93	0.92	0.6	0.81	0.71	0.62	0.75	0.87	0.89	0.55	0.89	0.92	0.78
Total Liab	0.63	0.6	0.44	-0.65	-0.66	0.62	0.53		0.63	-0.19	0.65	0.66	0.62	0.17	0.62	0.59	0.47	0.74	0.64	0.42	0.63	0.68	0.62
Total Current Assets	1.0	1.0	0.89	-0.93	-0.93	0.87	0.95	0.63		-0.65	0.98	0.96	0.59	0.6	0.74	0.61	0.77	0.89	0.9	0.7	0.9	0.94	0.89
Short Term Debt	-0.64	-0.65	-0.47	0.61	0.72	-0.64	-0.64	-0.19	-0.65		-0.65	-0.6	-0.42	-0.39	-0.6	-0.68	-0.59	-0.6	-0.53	-0.3	-0.53	-0.62	-0.48
Common Stock	0.98	0.98	0.88	-0.91	-0.95	0.9	0.93	0.65	0.98	-0.65		0.97	0.65	0.6	0.77	0.6	0.83	0.9	0.88	0.68	0.88	0.96	0.87
Net Tangible Assets	0.96	0.95	0.82	-0.88	-0.94	0.86	0.92	0.66	0.96	-0.6	0.97		0.78	0.59	0.86	0.65	0.8	0.88	0.84	0.61	0.84	0.91	0.82
Long Term Debt	0.59	0.58	0.4	-0.53	-0.71	0.57	0.6	0.62	0.59	-0.42	0.65	0.78		0.42	0.88	0.71	0.59	0.72	0.56	0.18	0.55	0.63	0.5
Net Receivables	0.6	0.62	0.68	-0.3	-0.55	0.35	0.81	0.17	0.6	-0.39	0.6	0.59	0.42		0.4	0.38	0.59	0.61	0.66	0.26	0.66	0.66	0.51
Deferred Long Term Liab	0.73	0.72	0.52	-0.69	-0.88	0.75	0.71	0.62	0.74	-0.6	0.77	0.86	0.88	0.4		0.85	0.74	0.69	0.53	0.37	0.52	0.65	0.54
Short Long Term Debt	0.61	0.6	0.37	-0.57	-0.77	0.6	0.62	0.59	0.61	-0.68	0.6	0.65	0.71	0.38	0.85		0.59	0.63	0.48	0.24	0.48	0.56	0.47
Property Plant Equipment	0.78	0.78	0.84	-0.72	-0.88	0.89	0.75	0.47	0.77	-0.59	0.83	0.8	0.59	0.59	0.74	0.59		0.65	0.59	0.7	0.58	0.74	0.76
Capital Surpluse	0.88	0.88	0.72	-0.8	-0.84	0.73	0.87	0.74	0.89	-0.6	0.9	0.88	0.72	0.61	0.69	0.63	0.65		0.94	0.44	0.94	0.97	0.82
Net Invested Capital	0.9	0.91	0.81	-0.81	-0.76	0.69	0.89	0.64	0.9	-0.53	0.88	0.84	0.56	0.66	0.53	0.48	0.59	0.94		0.56	1.0	0.96	0.88
Long Term Investments	0.72	0.71	0.85	-0.79	-0.65	0.78	0.55	0.42	0.7	-0.3	0.68	0.61	0.18	0.26	0.37	0.24	0.7	0.44	0.56		0.54	0.59	0.83
Net Working Capital	0.9	0.9	0.81	-0.8	-0.76	0.68	0.89	0.63	0.9	-0.53	0.88	0.84	0.55	0.66	0.52	0.48	0.58	0.94	1.0	0.54		0.96	0.87
Capital Stock	0.94	0.94	0.85	-0.85	-0.88	0.81	0.92	0.68	0.94	-0.62	0.96	0.91	0.63	0.66	0.65	0.56	0.74	0.97	0.96	0.59	0.96		0.89
Long Term Debt Total	0.89	0.89	0.92	-0.91	-0.81	0.85	0.78	0.62	0.89	-0.48	0.87	0.82	0.5	0.51	0.54	0.47	0.76	0.82	0.88	0.83	0.87	0.89

Click cells to compare fundamentals

Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.

Competition

Predict Syndax Pharmaceuticals

Syndax Return On Tangible Assets

Return On Tangible Assets

(0.36)

At this time, Syndax Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year.

According to the company disclosure, Syndax Pharmaceuticals has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Syndax Five Year Return Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syndax Pharmaceuticals' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics of similar companies.

Syndax Pharmaceuticals is currently under evaluation in five year return category among its peers.

Syndax Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Syndax Pharmaceuticals from analyzing Syndax Pharmaceuticals' financial statements. These drivers represent accounts that assess Syndax Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syndax Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	267.7M	918.7M	1.1B	1.5B	1.5B	1.6B
Enterprise Value	244.0M	824.0M	938.7M	1.5B	1.2B	1.3B

Syndax Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Syndax Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Syndax Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Syndax Fundamentals

	Return On Equity	-0.82
	Return On Asset	-0.49
	Operating Margin	(7.17) %
	Current Valuation	783.49 M
	Shares Outstanding	85.36 M
	Shares Owned By Insiders	0.81 %
	Shares Owned By Institutions	99.19 %
	Number Of Shares Shorted	14.4 M
	Price To Earning	126.11 X
	Price To Book	3.24 X
	Price To Sales	74.31 X
	Gross Profit	139.71 M
	EBITDA	(229.94 M)
	Net Income	(209.36 M)
	Cash And Equivalents	350.71 M
	Cash Per Share	5.82 X
	Total Debt	1.64 M
	Debt To Equity	0 %
	Current Ratio	17.19 X
	Book Value Per Share	4.28 X
	Cash Flow From Operations	(160.6 M)
	Short Ratio	6.54 X
	Earnings Per Share	(3.64) X
	Target Price	36.85
	Number Of Employees	184
	Beta	0.92
	Market Capitalization	1.19 B
	Total Asset	612.88 M
	Retained Earnings	(902.4 M)
	Working Capital	522.78 M
	Current Asset	79.72 M
	Current Liabilities	13.32 M
	Net Asset	612.88 M

About Syndax Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC